ADAM10 and cancer: Combination treatment of breast cancer cell lines with Herceptin and ADAM10 knockdown or inhibition potentiates the cancer-inhibiting effect of the antibody [29], suggesting that such combination therapy might overcome Herceptin resistance in patients.